<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction extraction-result-201 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extracted Data Details for extraction-result-201</h1>

        <div class="section">
            <h2>Extracted Data (Header)</h2>
            <div class="info-section">
                <p><strong>Extraction ID:</strong> extraction-result-201</p>
                <p><strong>Extraction Schema Used (ID):</strong> <a href="../schemas/extraction-schema-8.html">extraction-schema-8</a></p>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of specific brain cell types reported as most susceptible or most resilient in Alzheimer's disease, along with where and when this was observed, how it was measured, quantitative results, proposed mechanisms (including genetic risk enrichment), modifiers (e.g., sex, APOE), contradictions, and any causal/perturbational evidence.</div>
                <p><strong>Paper ID:</strong> paper-05724d1911ea1624440e45ab8c98fc92b8057591</p>
                <p><strong>Paper Title:</strong> <a href="https://www.semanticscholar.org/paper/05724d1911ea1624440e45ab8c98fc92b8057591" target="_blank">A Multi-network Approach Identifies Protein-Specific Co-expression in Asymptomatic and Symptomatic Alzheimer's Disease.</a></p>
                <p><strong>Paper Venue:</strong> Cell Systems</p>
                <p><strong>Paper TL;DR:</strong> Proteomic analyses of 129 human cortical tissues reveal protein- and disease-specific pathways involved in the etiology, initiation, and progression of Alzheimer's disease.</p>
                <p><strong>Cost:</strong> 0.02</p>
            </div>
        </div>

        <div class="section">
            <h2>Extracted Data (Details)</h2>
            <div class="extraction-instance-container" id="e201.0">
                <h3 class="extraction-instance">Extracted Data Instance 0 (e201.0)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of specific brain cell types reported as most susceptible or most resilient in Alzheimer's disease, along with where and when this was observed, how it was measured, quantitative results, proposed mechanisms (including genetic risk enrichment), modifiers (e.g., sex, APOE), contradictions, and any causal/perturbational evidence.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Neurons (synaptic)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Cortical neurons / synaptic neuronal proteins</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Neuronal and synaptic protein modules showed progressive downregulation in Asymptomatic AD (AsymAD) and AD, indicating neuronal/synaptic vulnerability beginning in preclinical stages measured at the protein level.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>cell_type_name</strong></td>
                            <td>cortical neuron (synaptic neuron)</td>
                        </tr>
                        <tr>
                            <td><strong>cell_subtype_or_state</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>cell_class</strong></td>
                            <td>excitatory/inhibitory neuron (general neuronal / synaptic compartment)</td>
                        </tr>
                        <tr>
                            <td><strong>markers_or_genes</strong></td>
                            <td>CAMK2A, CAMKK2, SYNGAP1, RTN1, L1CAM, GBRA1, GBRA2, OLFM1, NRXN3, SYNPO1, VGF, HOMER1</td>
                        </tr>
                        <tr>
                            <td><strong>brain_region_and_layer</strong></td>
                            <td>dorsolateral prefrontal cortex (FC, Brodmann area 9) and precuneus (PC, Brodmann area 7); no laminar detail provided</td>
                        </tr>
                        <tr>
                            <td><strong>species_or_model</strong></td>
                            <td>human postmortem AD (BLSA cohort; validated in Emory cohort)</td>
                        </tr>
                        <tr>
                            <td><strong>disease_stage_or_braak</strong></td>
                            <td>observed decreased in AsymAD and further decreased in symptomatic AD (AsymAD and AD comparisons; Braak/CERAD used as pathology metrics)</td>
                        </tr>
                        <tr>
                            <td><strong>susceptibility_label</strong></td>
                            <td>susceptible</td>
                        </tr>
                        <tr>
                            <td><strong>measurement_type</strong></td>
                            <td>label-free quantitative proteomics (LC-MS/MS, MaxQuant LFQ) with WGCNA protein co-expression modules (eigenprotein correlations) and differential expression (ANOVA/Tukey)</td>
                        </tr>
                        <tr>
                            <td><strong>quantitative_change</strong></td>
                            <td>Module eigenproteins (B-M1 and B-M4) were significantly decreased in AD and already decreased in AsymAD versus controls (no single fold-change for module provided); overall 362 proteins significantly altered across regions (ANOVA p<0.01); neuronal protein overlap correlation with cognate RNA cor=0.53 for module-associated proteins vs global RNA-protein cor=0.25</td>
                        </tr>
                        <tr>
                            <td><strong>pathology_measured</strong></td>
                            <td>amyloid (CERAD) and neurofibrillary tangles (Braak); cognitive status (clinical symptom group: control, AsymAD, AD)</td>
                        </tr>
                        <tr>
                            <td><strong>associations_with_pathology</strong></td>
                            <td>B-M1 and B-M4 (neuronal modules) negatively correlated with CERAD and Braak scores (textual significance reported; specific correlation values not given for these modules in text)</td>
                        </tr>
                        <tr>
                            <td><strong>spatial_or_proximity_context</strong></td>
                            <td>No finer spatial/proximity context provided beyond FC and PC regions</td>
                        </tr>
                        <tr>
                            <td><strong>mechanism_hypothesis</strong></td>
                            <td>Loss of synaptic proteins reflects synapse/neuronal loss and synaptic dysfunction; may precede cognitive symptoms; could result from tau pathology (hyperphosphorylation) and microtubule dysfunction causing neurite/transport deficits</td>
                        </tr>
                        <tr>
                            <td><strong>ad_gwas_gene_enrichment</strong></td>
                            <td>AD GWAS candidates were not primarily enriched in neuronal modules in proteome; rather ASD and schizophrenia GWAS candidates enriched in neuronal modules. (No AD-GWAS enrichment reported for neuronal modules in this paper.)</td>
                        </tr>
                        <tr>
                            <td><strong>perturbation_or_causal_evidence</strong></td>
                            <td>No direct genetic or pharmacologic perturbation evidence in this study; evidence is observational proteomic correlation across disease stages.</td>
                        </tr>
                        <tr>
                            <td><strong>modifiers_and_risk_factors</strong></td>
                            <td>Analyses adjusted for age, sex, and postmortem interval. APOE genotype included in metadata but no interaction effects on neuronal module reported in text.</td>
                        </tr>
                        <tr>
                            <td><strong>comorbid_pathologies</strong></td>
                            <td>Some neuronal-module decreases were AD-specific in Emory cohort vs PD/ALS (decrease selectively observed in AD for E-M7/E-M15 overlapping B-M1).</td>
                        </tr>
                        <tr>
                            <td><strong>comparisons_to_other_cell_types</strong></td>
                            <td>Neuronal modules decreased while astrocyte/microglial modules increased with pathology; neuronal changes occur early (AsymAD) compared to some glial modules which increase later (symptomatic).</td>
                        </tr>
                        <tr>
                            <td><strong>contradictory_or_null_findings</strong></td>
                            <td>No direct contradiction in this paper; authors note that many proteomic modules (e.g., microtubule-related) are not captured by transcriptome, indicating RNA-protein discordance rather than contradiction about neuronal vulnerability.</td>
                        </tr>
                        <tr>
                            <td><strong>replication_or_cross_cohort_validation</strong></td>
                            <td>Findings replicated in independent Emory cohort: decreases in neuronal/synaptic protein-enriched modules (E-M7 and E-M15 overlapping B-M1) were observed selectively in AD; 13/16 BLSA modules preserved in Emory (Zsummary>2).</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_and_counts</strong></td>
                            <td>BLSA: 50 individuals (15 controls, 15 AsymAD, 20 AD), 97 samples (47 FC, 50 PC); Proteome: 2,735 protein groups quantified in ≥90% of samples. Emory validation: n=8 per group (control, AD, PD, ALS), 2,491 proteins quantified.</td>
                        </tr>
                        <tr>
                            <td><strong>dataset_or_platform</strong></td>
                            <td>Label-free LC-MS/MS on Orbitrap Q-Exactive; MaxQuant LFQ quantification; WGCNA co-expression analysis; validation Emory cohort proteomics</td>
                        </tr>
                        <tr>
                            <td><strong>functional_impact</strong></td>
                            <td>Loss of synaptic proteins consistent with synapse loss (major correlate of cognitive impairment), and observed decreases correlate with neuropathology and progression from AsymAD to symptomatic AD.</td>
                        </tr>
                        <tr>
                            <td><strong>key_evidence_snippet</strong></td>
                            <td>“Decreased expression of the B-M1 and B-M4 modules in AsymAD indicates loss of synaptic proteins prior to the onset of cognitive impairment.”</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': "A Multi-network Approach Identifies Protein-Specific Co-expression in Asymptomatic and Symptomatic Alzheimer's Disease.", 'publication_date_yy_mm': '2017-01'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e201.1">
                <h3 class="extraction-instance">Extracted Data Instance 1 (e201.1)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of specific brain cell types reported as most susceptible or most resilient in Alzheimer's disease, along with where and when this was observed, how it was measured, quantitative results, proposed mechanisms (including genetic risk enrichment), modifiers (e.g., sex, APOE), contradictions, and any causal/perturbational evidence.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Astrocytes</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Astrocyte / astroglial cell-related protein modules</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Astrocyte-enriched protein modules (inflammatory/astroglial modules) are upregulated in AsymAD and AD, correlate with neuropathology and clinical symptoms, and are enriched for AD genetic risk loci suggesting a potentially causal role.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>cell_type_name</strong></td>
                            <td>astrocyte (astroglia)</td>
                        </tr>
                        <tr>
                            <td><strong>cell_subtype_or_state</strong></td>
                            <td>reactive/inflammatory astrocyte-like module (inflammatory response; extracellular matrix)</td>
                        </tr>
                        <tr>
                            <td><strong>cell_class</strong></td>
                            <td>astrocyte (glial)</td>
                        </tr>
                        <tr>
                            <td><strong>markers_or_genes</strong></td>
                            <td>GFAP, PBXIP1, GJA1, SLC1A1 (SLCA11 in text), ALDOC, GCSH, clusterin (CLU), HSPB1/HSP27</td>
                        </tr>
                        <tr>
                            <td><strong>brain_region_and_layer</strong></td>
                            <td>dorsolateral prefrontal cortex (FC) and precuneus (PC); no laminar detail provided</td>
                        </tr>
                        <tr>
                            <td><strong>species_or_model</strong></td>
                            <td>human postmortem AD (BLSA; validated in Emory cohort)</td>
                        </tr>
                        <tr>
                            <td><strong>disease_stage_or_braak</strong></td>
                            <td>B-M6 (astrocyte/inflammatory) increased in AsymAD and AD; B-M5 (extracellular matrix, astrocyte/microglial markers) increased in symptomatic AD (correlated with Braak)</td>
                        </tr>
                        <tr>
                            <td><strong>susceptibility_label</strong></td>
                            <td>susceptible (reactive/increase in AD; implicated in disease progression)</td>
                        </tr>
                        <tr>
                            <td><strong>measurement_type</strong></td>
                            <td>label-free proteomics (LC-MS/MS LFQ), WGCNA module eigenprotein correlations with CERAD/Braak and clinical groups (control, AsymAD, AD); GO and cell-type enrichment using reference proteomes</td>
                        </tr>
                        <tr>
                            <td><strong>quantitative_change</strong></td>
                            <td>Modules B-M6 and B-M5 showed positive correlation with CERAD and/or Braak; B-M6 increased between control and AsymAD and between AsymAD and AD (exact fold-changes for module not provided). In Emory cohort, E-M3, E-M4, E-M21 (overlapping B-M5/B-M6) were significantly increased in AD vs PD/ALS/controls.</td>
                        </tr>
                        <tr>
                            <td><strong>pathology_measured</strong></td>
                            <td>amyloid plaques (CERAD), neurofibrillary tangles (Braak), and clinical cognitive status</td>
                        </tr>
                        <tr>
                            <td><strong>associations_with_pathology</strong></td>
                            <td>Astrocyte-related modules positively correlated with CERAD and/or Braak; B-M5 correlated exclusively with Braak stage (textual statement). Exact correlation coefficients not provided for B-M6/B-M5 in text.</td>
                        </tr>
                        <tr>
                            <td><strong>spatial_or_proximity_context</strong></td>
                            <td>No spatial proximity detail other than brain region (FC and PC)</td>
                        </tr>
                        <tr>
                            <td><strong>mechanism_hypothesis</strong></td>
                            <td>Upregulation may reflect astrocyte activation/proliferation and neuroinflammatory response that associates with cognitive decline; astrocyte-related networks may mediate AD genetic risk and contribute to disease progression.</td>
                        </tr>
                        <tr>
                            <td><strong>ad_gwas_gene_enrichment</strong></td>
                            <td>AD GWAS candidate proteins were over-represented in astrocyte/microglia extracellular matrix module B-M5 (11 candidate genes mapped to B-M5 including APOE, CLU, FERMT2); enrichment remained significant after omitting APOE.</td>
                        </tr>
                        <tr>
                            <td><strong>perturbation_or_causal_evidence</strong></td>
                            <td>No direct perturbational experiments in this paper; genetic enrichment (GWAS) in astrocyte modules is presented as supportive of causal role but is associative.</td>
                        </tr>
                        <tr>
                            <td><strong>modifiers_and_risk_factors</strong></td>
                            <td>Analyses controlled for age, sex, and PMI; APOE present in B-M5 but enrichment not driven solely by APOE. No sex-specific or APOE-interaction analyses reported.</td>
                        </tr>
                        <tr>
                            <td><strong>comorbid_pathologies</strong></td>
                            <td>Some astrocyte/microglial modules (overlapping) showed changes that were AD-specific in Emory cohort vs PD and ALS, indicating disease specificity for portions of the astroglial response.</td>
                        </tr>
                        <tr>
                            <td><strong>comparisons_to_other_cell_types</strong></td>
                            <td>Astrocyte/microglial modules increased in AD while neuronal modules decreased; glial modules map to AD GWAS loci whereas neuronal modules map to ASD/SCZ loci in transcriptome analyses.</td>
                        </tr>
                        <tr>
                            <td><strong>contradictory_or_null_findings</strong></td>
                            <td>No direct contradictions reported; authors note many proteomic modules (including inflammatory ones) are not well-represented in transcriptome, indicating RNA-protein discordance.</td>
                        </tr>
                        <tr>
                            <td><strong>replication_or_cross_cohort_validation</strong></td>
                            <td>Astrocyte/microglial module signals (B-M5/B-M6) were preserved in Emory proteome: 13/16 BLSA modules preserved; Emory modules E-M3, E-M4, E-M21 (overlapping B-M5/B-M6) were significantly increased in AD vs other diseases.</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_and_counts</strong></td>
                            <td>BLSA: 50 individuals (15 controls, 15 AsymAD, 20 AD), 97 samples (47 FC, 50 PC); Emory validation: n=8 per group (control, AD, PD, ALS). Proteome: 2,735 proteins quantified in BLSA matrix.</td>
                        </tr>
                        <tr>
                            <td><strong>dataset_or_platform</strong></td>
                            <td>Label-free LC-MS/MS (Orbitrap Q-Exactive), MaxQuant LFQ, WGCNA, GO-Elite, MAGMA for GWAS enrichment</td>
                        </tr>
                        <tr>
                            <td><strong>functional_impact</strong></td>
                            <td>Increased astrocyte/inflammatory protein modules associated with neuropathology and symptom onset; authors suggest these glial responses may mediate cognitive decline.</td>
                        </tr>
                        <tr>
                            <td><strong>key_evidence_snippet</strong></td>
                            <td>“B-M6, linked to ‘inflammatory response', is also increased in AsymAD, which may reflect phenotypic activation and/or proliferation of astrocytes and microglia prior to cognitive decline.”</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': "A Multi-network Approach Identifies Protein-Specific Co-expression in Asymptomatic and Symptomatic Alzheimer's Disease.", 'publication_date_yy_mm': '2017-01'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e201.2">
                <h3 class="extraction-instance">Extracted Data Instance 2 (e201.2)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of specific brain cell types reported as most susceptible or most resilient in Alzheimer's disease, along with where and when this was observed, how it was measured, quantitative results, proposed mechanisms (including genetic risk enrichment), modifiers (e.g., sex, APOE), contradictions, and any causal/perturbational evidence.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Microglia</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Microglia / microglial cell-related protein modules</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Microglia-enriched protein modules are upregulated in AD and strongly correlate with tau pathology and cognitive decline, and AD GWAS candidates are enriched in microglial-associated transcript and protein modules, implicating microglia in causal AD risk.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>cell_type_name</strong></td>
                            <td>microglia</td>
                        </tr>
                        <tr>
                            <td><strong>cell_subtype_or_state</strong></td>
                            <td>activated/inflammatory microglial-state (microglia/astrocyte inflammatory module); peripheral immune protein deposition module noted (blood-derived) distinct from canonical microglial module</td>
                        </tr>
                        <tr>
                            <td><strong>cell_class</strong></td>
                            <td>microglia (glial/immune)</td>
                        </tr>
                        <tr>
                            <td><strong>markers_or_genes</strong></td>
                            <td>MSN, LCP1, LSP1, C1QC, ANXA1, ANXA4, CTSZ, CLIC; AD GWAS candidates enriched in microglial transcript module include HMHA1, MS4A6A, CD2AP, MS4A4A, HLA-DRA, FERMT2</td>
                        </tr>
                        <tr>
                            <td><strong>brain_region_and_layer</strong></td>
                            <td>dorsolateral prefrontal cortex (FC) and precuneus (PC); no laminar detail provided</td>
                        </tr>
                        <tr>
                            <td><strong>species_or_model</strong></td>
                            <td>human postmortem AD (BLSA; Emory validation); transcriptome dataset from human prefrontal cortex (Narayanan et al. 2014)</td>
                        </tr>
                        <tr>
                            <td><strong>disease_stage_or_braak</strong></td>
                            <td>Microglial modules (protein and transcript modules) increased in AD and some increased already in AsymAD (B-M6 increased in AsymAD; specific microglial modules increased in symptomatic AD such as B-M5)</td>
                        </tr>
                        <tr>
                            <td><strong>susceptibility_label</strong></td>
                            <td>susceptible (increased activation/inflammatory state associated with AD progression)</td>
                        </tr>
                        <tr>
                            <td><strong>measurement_type</strong></td>
                            <td>proteomics (LFQ LC-MS/MS) with WGCNA module analysis; transcriptomic co-expression modules (microarray-derived WGCNA) compared and integrated; MAGMA GWAS enrichment performed</td>
                        </tr>
                        <tr>
                            <td><strong>quantitative_change</strong></td>
                            <td>Multiple modules positively correlated with CERAD and/or Braak (e.g., B-M6 inflammatory, B-M5 extracellular matrix) and module eigenproteins increased between control, AsymAD and AD (exact fold-changes not provided). Transcriptome microglial module T-M3 contained 33 GWAS candidates; proteome module B-M5 contained 11 GWAS candidate genes.</td>
                        </tr>
                        <tr>
                            <td><strong>pathology_measured</strong></td>
                            <td>amyloid plaques (CERAD), neurofibrillary tangles (Braak), cognitive status</td>
                        </tr>
                        <tr>
                            <td><strong>associations_with_pathology</strong></td>
                            <td>Microglial-enriched protein and transcript modules were among the most significantly increased in AD and strongly correlated with neurofibrillary tangle pathology and cognitive decline (textual statement; specific r/p-values not provided for these modules in text).</td>
                        </tr>
                        <tr>
                            <td><strong>spatial_or_proximity_context</strong></td>
                            <td>No spatial proximity details to plaques provided; separate protein module (E-M19) included plasma/blood proteins possibly from blood-brain barrier leakage, which may influence microglial activation.</td>
                        </tr>
                        <tr>
                            <td><strong>mechanism_hypothesis</strong></td>
                            <td>Microglial activation and inflammatory responses may drive or mediate neurodegeneration and cognitive symptoms; enrichment of AD GWAS loci in microglial modules suggests genetic predisposition operating through microglial biology.</td>
                        </tr>
                        <tr>
                            <td><strong>ad_gwas_gene_enrichment</strong></td>
                            <td>Yes — AD GWAS candidates enriched in microglia-associated modules: proteome B-M5 contained 11 candidate genes (including APOE, CLU, FERMT2); transcriptome T-M3 (microglial/endothelial) enriched with 33 GWAS candidates (HMHA1, MS4A6A, CD2AP, MS4A4A, HLA-DRA, FERMT2).</td>
                        </tr>
                        <tr>
                            <td><strong>perturbation_or_causal_evidence</strong></td>
                            <td>No direct perturbational experiments in this paper; genetic enrichment (GWAS mapping via MAGMA) is presented as evidence consistent with a causal role but is associative.</td>
                        </tr>
                        <tr>
                            <td><strong>modifiers_and_risk_factors</strong></td>
                            <td>Analyses adjusted for age, sex and PMI; APOE included among GWAS candidates; no explicit modifier interactions (sex/APOE stratified effects) reported in text.</td>
                        </tr>
                        <tr>
                            <td><strong>comorbid_pathologies</strong></td>
                            <td>Some inflammatory/extracellular modules overlap with modules that increase across AD, PD, and ALS (E-M9, E-M19), indicating shared neurodegeneration-related inflammation; other microglial/astrocyte modules were AD-specific in Emory cohort.</td>
                        </tr>
                        <tr>
                            <td><strong>comparisons_to_other_cell_types</strong></td>
                            <td>Microglial modules increased while neuronal modules decreased; AD genetic risk loci map preferentially to microglia/oligodendrocyte modules rather than neuronal modules.</td>
                        </tr>
                        <tr>
                            <td><strong>contradictory_or_null_findings</strong></td>
                            <td>No direct contradictions in this paper; however authors note many proteome modules do not overlap with transcriptome, so some microglial-related proteomic changes might not be fully captured at mRNA level.</td>
                        </tr>
                        <tr>
                            <td><strong>replication_or_cross_cohort_validation</strong></td>
                            <td>Microglial/astrocyte-related modules were preserved in Emory cohort (module overlap and Emory modules E-M3/E-M4/E-M21 overlapped with B-M5/B-M6 and were increased in AD). 13 of 16 BLSA modules preserved in Emory (Zsummary>2).</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_and_counts</strong></td>
                            <td>BLSA: 50 individuals (15 controls, 15 AsymAD, 20 AD), 97 samples (47 FC, 50 PC); Emory: n=8 per group (control, AD, PD, ALS). Proteome BLSA quantified 2,735 proteins; transcriptome dataset used for comparison: microarray n=308 AD and n=157 controls (Narayanan et al. 2014).</td>
                        </tr>
                        <tr>
                            <td><strong>dataset_or_platform</strong></td>
                            <td>Label-free LC-MS/MS proteomics with MaxQuant LFQ and WGCNA; transcriptome microarray (GEO GSE33000) used for RNA network; MAGMA for GWAS enrichment</td>
                        </tr>
                        <tr>
                            <td><strong>functional_impact</strong></td>
                            <td>Authors propose that increases in microglial protein networks are associated with clinical symptoms and may mediate cognitive decline, linking microglial biology to AD pathogenesis.</td>
                        </tr>
                        <tr>
                            <td><strong>key_evidence_snippet</strong></td>
                            <td>“Protein and RNA networks enriched in microglial proteins were significantly increased in AD and strongly correlated with both neurofibrillary tangle pathology and cognitive decline.”</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': "A Multi-network Approach Identifies Protein-Specific Co-expression in Asymptomatic and Symptomatic Alzheimer's Disease.", 'publication_date_yy_mm': '2017-01'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e201.3">
                <h3 class="extraction-instance">Extracted Data Instance 3 (e201.3)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of specific brain cell types reported as most susceptible or most resilient in Alzheimer's disease, along with where and when this was observed, how it was measured, quantitative results, proposed mechanisms (including genetic risk enrichment), modifiers (e.g., sex, APOE), contradictions, and any causal/perturbational evidence.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Oligodendrocytes / myelin</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Oligodendrocyte / myelination-related protein modules</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>An oligodendrocyte/myelin protein module (B-M2) was identified (enriched for myelin proteins) and AD GWAS candidates (including BIN1, PICALM) were over-represented in this module, linking oligodendrocyte biology to AD genetic risk though the module's directional change in AD proteome was not emphasized as a primary susceptible/resilient signal.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>cell_type_name</strong></td>
                            <td>oligodendrocyte</td>
                        </tr>
                        <tr>
                            <td><strong>cell_subtype_or_state</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>cell_class</strong></td>
                            <td>oligodendrocyte (glial)</td>
                        </tr>
                        <tr>
                            <td><strong>markers_or_genes</strong></td>
                            <td>CNP, MAG, MOG, PLP1, MBP, BIN1, PICALM (GWAS candidates mapped to this module)</td>
                        </tr>
                        <tr>
                            <td><strong>brain_region_and_layer</strong></td>
                            <td>dorsolateral prefrontal cortex (FC) and precuneus (PC); no laminar detail provided</td>
                        </tr>
                        <tr>
                            <td><strong>species_or_model</strong></td>
                            <td>human postmortem AD (BLSA) and transcriptome comparison</td>
                        </tr>
                        <tr>
                            <td><strong>disease_stage_or_braak</strong></td>
                            <td>Not strongly characterized as increased or decreased in the proteomic results text; module identified and evaluated for GWAS enrichment; transcriptome T-M13 (oligodendrocyte) enriched with AD GWAS candidates.</td>
                        </tr>
                        <tr>
                            <td><strong>susceptibility_label</strong></td>
                            <td>mixed/region-specific (module identified; genetic-risk enrichment suggests involvement/causal relevance but directional vulnerability in proteome not clearly stated)</td>
                        </tr>
                        <tr>
                            <td><strong>measurement_type</strong></td>
                            <td>label-free proteomics (LC-MS/MS LFQ) with WGCNA; MAGMA gene-level GWAS enrichment analysis</td>
                        </tr>
                        <tr>
                            <td><strong>quantitative_change</strong></td>
                            <td>24 AD GWAS candidate genes mapped to B-M2 (including BIN1 and PICALM) by MAGMA (gene-level threshold -log p > 1.3). No explicit module eigenprotein directional change (increase/decrease) quantified in text for B-M2.</td>
                        </tr>
                        <tr>
                            <td><strong>pathology_measured</strong></td>
                            <td>GERAD/CERAD and Braak staging were used across study, but specific associations between B-M2 and CERAD/Braak are not reported in text.</td>
                        </tr>
                        <tr>
                            <td><strong>associations_with_pathology</strong></td>
                            <td>AD GWAS enrichment is reported for the oligodendrocyte B-M2 module (24 candidate genes), suggesting genetic association rather than direct proteomic correlation with neuropathology reported in text.</td>
                        </tr>
                        <tr>
                            <td><strong>spatial_or_proximity_context</strong></td>
                            <td>No spatial/proximity detail beyond FC and PC regional sampling.</td>
                        </tr>
                        <tr>
                            <td><strong>mechanism_hypothesis</strong></td>
                            <td>Enrichment of AD GWAS loci in oligodendrocyte/myelin module suggests oligodendrocyte dysfunction or myelin-related processes may contribute causally to AD pathogenesis (genetic risk acts through oligodendrocyte networks).</td>
                        </tr>
                        <tr>
                            <td><strong>ad_gwas_gene_enrichment</strong></td>
                            <td>Yes — 24 candidate AD GWAS genes mapped to B-M2 (including BIN1, PICALM); at transcriptome level T-M13 (oligodendrocyte module) enriched with 27 AD GWAS candidates including BIN1.</td>
                        </tr>
                        <tr>
                            <td><strong>perturbation_or_causal_evidence</strong></td>
                            <td>No experimental perturbation performed in this study; genetic association via GWAS enrichment presented as supportive evidence toward causal involvement but not direct causation.</td>
                        </tr>
                        <tr>
                            <td><strong>modifiers_and_risk_factors</strong></td>
                            <td>Analyses accounted for age, sex, PMI; no modifier effects (e.g., APOE interactions) for oligodendrocyte module specifically reported.</td>
                        </tr>
                        <tr>
                            <td><strong>comorbid_pathologies</strong></td>
                            <td>Not specifically discussed for oligodendrocyte module in text; some cytoskeletal/microtubule modules showed changes that were AD-specific or shared across diseases.</td>
                        </tr>
                        <tr>
                            <td><strong>comparisons_to_other_cell_types</strong></td>
                            <td>AD GWAS enrichment concentrated in glial-related modules (microglia and oligodendrocytes) in both proteome and transcriptome, in contrast to neuronal modules which were not enriched for AD GWAS candidates.</td>
                        </tr>
                        <tr>
                            <td><strong>contradictory_or_null_findings</strong></td>
                            <td>The study did not report a clear directional proteomic change for oligodendrocyte module B-M2, making susceptibility/resilience uncertain; authors emphasize GWAS enrichment rather than module dysregulation magnitude.</td>
                        </tr>
                        <tr>
                            <td><strong>replication_or_cross_cohort_validation</strong></td>
                            <td>Module membership and GWAS mapping were consistent across proteome and transcriptome analyses and preserved in Emory network overlap (B-M2 overlaps with Emory modules; 13/16 modules preserved), supporting robustness of module identification.</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_and_counts</strong></td>
                            <td>BLSA: 50 individuals (15 controls, 15 AsymAD, 20 AD), 97 samples; Emory and transcriptome cohorts also used (Emory n=8 per group; transcriptome microarray n=308 AD, n=157 controls for WGCNA).</td>
                        </tr>
                        <tr>
                            <td><strong>dataset_or_platform</strong></td>
                            <td>Label-free LC-MS/MS proteomics (Orbitrap Q-Exactive), MaxQuant LFQ, WGCNA for co-expression; MAGMA used to map GWAS summary statistics to genes/modules</td>
                        </tr>
                        <tr>
                            <td><strong>functional_impact</strong></td>
                            <td>Authors suggest oligodendrocyte/myelin-related processes may be a conduit for AD genetic risk and could influence disease etiology and progression (functional consequences not directly measured here).</td>
                        </tr>
                        <tr>
                            <td><strong>key_evidence_snippet</strong></td>
                            <td>“In the BLSA network, translated protein products from AD candidate genes ... were over-represented in the oligodendrocyte (B-M2) and astrocyte/microglia (B-M5) extracellular matrix protein modules. A total of 24 candidate genes mapped to B-M2 including BIN1 and PICALM.”</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': "A Multi-network Approach Identifies Protein-Specific Co-expression in Asymptomatic and Symptomatic Alzheimer's Disease.", 'publication_date_yy_mm': '2017-01'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <div class="section">
            <h2>Potentially Relevant New Papers (mentioned by this paper)</h2>
            <ol>
                <li>Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer's disease <em>(Rating: 2)</em></li>
                <li>Genes and pathways underlying regional and cell type changes in Alzheimer's disease <em>(Rating: 2)</em></li>
                <li>A systems level analysis of transcriptional changes in Alzheimer’s disease and normal aging <em>(Rating: 2)</em></li>
                <li>An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex <em>(Rating: 1)</em></li>
                <li>Common dysregulation network in the human prefrontal cortex underlies two neurodegenerative diseases <em>(Rating: 1)</em></li>
            </ol>
        </div>

        </div>

    </div>
</body>
</html>